Heart failure & cardiomyopathies

Atrial Fibrillation/Flutter in Transthyretin Cardiac Amyloidosis: Prevalence, Incidence, Clinical Predictors, and Effect of Tafamidis

JACC AdvPublished Retrospective cohort study

Authors' conclusion

More than half of the ATTR-CA patients have AF, which was associated with wild-type amyloid transthyretin, greater Columbia stage, and increased LAVI. About half of the ATTR-CA individuals developed AF after 2 years, which was predicted by the Columbia score, but not the CHARGE-AF score. ATTRv and tafamidis were protective against incident AF.

Study context

Population
Patients with transthyretin cardiac amyloidosis (ATTR-CA)
Participants
419 patients
Outcome
Predictors of prevalent and incident AF (atrial fibrillation/flutter), and effect of tafamidis

Main finding

As reported in the abstract

baseline
Odds ratio (95% CI)P value
Higher Columbia scoreprevalent AF
1.48(1.25–1.75)
P < 0.05
Higher LAVIprevalent AF
1.05(1.02–1.08)
P < 0.05
ATTRvprevalent AF; protective
0.19(0.07–0.55)
P < 0.05
Atrial fibrillation/flutter (AF) present at baseline
58% (n = 244)

Observational data: associations, not effects.

Further findings

Incident AF in patients without prior AF (Cox regression) · median follow-up 2 years

HR (95% CI)P value
Higher Columbia scoreNew onset AF1.18 (1.01–1.38)P = 0.035
ATTRvProtective0.44 (0.23–0.87)P = 0.017
TafamidisProtective0.54 (0.30–0.95)P = 0.034
Incident AF in patients without prior AF (Cox regression) — Incident AF in subjects without prior AF
71 (41%)

Incident AF in patients without prior AF (Cox regression) · median follow-up 2 years

CHARGE-AF and left atrial volume index (LAVI) not associated with new onset AF

Original publication

Atrial Fibrillation/Flutter in Transthyretin Cardiac Amyloidosis: Prevalence, Incidence, Clinical Predictors, and Effect of Tafamidis. JACC Adv. Published 24 December 2025. doi:10.1016/j.jacadv.2025.102470

Composed by AI from the published abstract and checked against it. How Briefs are made →

Get them every week

New studies on this topic in My Week and in your Monday e-mail.

We e-mail you a sign-in link and a code. No password, no spam.